Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
SAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, will present at Guggenheim’s 6th Annual Biotechnology Conference.
Related news for (ANAB)
- From Real Estate Reinvention to Biotech Breakouts- These Are the Stocks to Watch into the Close
- MoBot alert highlights: NASDAQ: NKGN, NYSE: BBAI.WS, NASDAQ: MYNA, NASDAQ: ARQT, NASDAQ: ANAB (02/12/25 03:00 PM)
- MoBot alert highlights: NASDAQ: WISA, NASDAQ: TIVC, NASDAQ: NEUP, NASDAQ: NKGN, NASDAQ: ANAB (02/12/25 08:00 AM)
- Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals